Dawson John Andrew reports ownership in PDS Biotechnology Corp

Dawson John Andrew has officially reported his ownership in PDS Biotechnology Corp, where he serves as a director. This filing is significant as it emphasizes the importance of transparency in corporate governance, particularly in the pharmaceutical industry.

PDS Biotechnology Corp, identified by CIK 0001472091 and operating under the SIC code for Pharmaceutical Preparations, is based in Princeton, New Jersey. The company has been active in the life sciences sector, focusing on innovative therapies.

According to the recent filing dated October 21, 2026, Andrew disclosed that he owns one security in PDS Biotechnology. The filing states, "Dawson John Andrew is a director at PDS Biotechnology Corp." This highlights his ongoing commitment to the company and its strategic direction.

This development may affect various stakeholders, including investors, employees, and competitors, as they assess the potential impact of Andrew's leadership on the company's future. Transparency in ownership and governance is crucial for maintaining trust and confidence among these groups.

The filing does not specify what actions may follow this disclosure, leaving some uncertainty about the immediate next steps for Andrew and PDS Biotechnology.

Details of the Filing

The Form 3 filing was submitted on October 21, 2026, and pertains to the reporting period ending on October 18, 2026. This document confirms that Dawson John Andrew holds one security in PDS Biotechnology Corp, emphasizing his role as a director within the company.

PDS Biotechnology Corp is incorporated in Delaware and operates under the trading symbol PDSB. The company focuses on pharmaceutical preparations, specifically in the life sciences sector, which underscores its commitment to developing innovative therapies.

"Dawson John Andrew is a director at PDS Biotechnology Corp," the filing states, further highlighting the importance of his position in guiding the company's strategic initiatives.

Additionally, the filing indicates that Dawson is not an officer or a ten percent owner of the company, which may suggest a specific focus on his directorial responsibilities rather than broader ownership interests.

The filing does not provide any information regarding Andrew's previous ownership or any potential plans for future transactions related to his security in PDS Biotechnology Corp.